New and Emerging ALK/ROS1/NTRK-Targeted Agents in NSCLC: Addressing Treatment Resistance and CNS Metastases
CE Information1.0 CME credit
Completion Time60 minutes
Available UntilJanuary 20, 2024
Posted ByHMP Global
SpecialtiesHematology / Oncology
Clinical TopicsLung Cancer
This on-demand webcast is available with synchronized slides and video/audio.
To be eligible for credit, participants must complete the educational activity, complete the 4-question post-test with a minimum score of 70%, and complete the activity evaluation form. Upon completing the activity, there will be instructions on how to complete the evaluation and print a certificate or other documentation of credit.
Release Date: January 20, 2023.
Expiration Date: January 20, 2024.
Estimated Time to Complete: 1.00 hour
There is no fee associated with this activity.
After participating in this activity, learners should be better able to:
- Assess guideline recommendations, testing techniques, and clinical applications for molecular profiling to identify patients who will benefit from ALK, ROS1, or NTRK-targeted therapy
- Evaluate clinical efficacy and safety data for new and emerging ALK, ROS1, and NTRK-targeted agents against treatment resistance and CNS metastases
- Utilize adverse event management strategies to optimize treatment efficacy and mitigate treatment risks
This activity offers 1.0 CME credit to attendees.